

# NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT07305818

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Merida Biosciences
Enrollment	100 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Adults 18 to 55 years of age, inclusive, at the time of signing the ICF
- Documented GD diagnosis,
- Receiving stable dose of ATD (Antithyroid drug)
- Body weight at least 50 kg (110 lb) and body mass index (BMI) 18.0-35.0 kg/m<sup>2</sup>, inclusive
- Women of childbearing potential must agree to use highly effective contraceptive methods
- ... and 3 more (see full listing online)

### Exclusion (38)

- History of:
  - total thyroidectomy.
  - History of hyperthyroidism not caused by GD (eg, toxic adenoma, toxic multinodular goiter).
  - History of thyroid storm.
  - History of agranulocytosis, anemia, leukopenia, thrombocytopenia, vasculitis, or liver toxicity due to prior ATD therapy Treatment with RAI therapy within 12 months prior to Screening
- ... and 33 more (see full listing online)

## Locations (6 total)

---

Site # 1103, Phoenix, Arizona, United States  
Site # 1101, Hollywood, Florida, United States  
Site # 1102, Rochester, Minnesota, United States  
... and 3 more locations